Biotech Stock Valuations and Public Policy: Will “Buy” Ratings Make “21st Century Cures” A Tough Sell?
This article was originally published in RPM Report
Executive Summary
Wall Street remains enthusiastic about the prospects for biotechnology firms, with share prices up again to start 2015 after another year of big gains in 2014. But will all the “buy” ratings make it harder for the biopharma industry to sell Congress on the need for pro-innovation reforms?
You may also be interested in...
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.
US FDA Gene Therapy Staff-Up: Glass Three-Quarters Full?
Aggressive staffing goals for FDA’s gene and cell therapy review group might not be fully achieved – but the head of CBER believes the new organization is on track to deliver on his high expectations going forward.